In vivo anti-tumour activity of recombinant human tumour necrosis factor-alpha against Meth-A sarcoma requires L3T4-positive T cells
Ann Inst Pasteur Immunol
.
1988 May-Jun;139(3):299-301.
doi: 10.1016/0769-2625(88)90144-4.
Authors
M A Palladino
1
,
I S Figari
Affiliation
1
Genentech, Inc., South San Francisco, CA 94080.
PMID:
2901845
DOI:
10.1016/0769-2625(88)90144-4
No abstract available
MeSH terms
Animals
CD4-Positive T-Lymphocytes / immunology*
Mice
Sarcoma, Experimental / drug therapy
Sarcoma, Experimental / immunology
Tumor Necrosis Factor-alpha / pharmacology*
Substances
Tumor Necrosis Factor-alpha